Business Description
Pacira BioSciences Inc
NAICS : 325412
SIC : 2834
ISIN : US6951271005
Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.7 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.86 | |||||
| Debt-to-EBITDA | 19.28 | |||||
| Interest Coverage | 8.29 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.06 | |||||
| Beneish M-Score | -3.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.7 | |||||
| 3-Year EBITDA Growth Rate | 26.9 | |||||
| 3-Year EPS without NRI Growth Rate | -32.2 | |||||
| 3-Year FCF Growth Rate | 44 | |||||
| 3-Year Book Growth Rate | 9.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.88 | |||||
| Future 3-5Y Total Revenue Growth Rate | 4.66 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.95 | |||||
| 9-Day RSI | 48.05 | |||||
| 14-Day RSI | 51.35 | |||||
| 6-1 Month Momentum % | -42.28 | |||||
| 12-1 Month Momentum % | -34.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.48 | |||||
| Days Inventory | 210.09 | |||||
| Days Sales Outstanding | 53.53 | |||||
| Days Payable | 32.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | 4.48 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.35 | |||||
| Operating Margin % | 14.68 | |||||
| Net Margin % | -13.06 | |||||
| FCF Margin % | 27.84 | |||||
| ROE % | -10.74 | |||||
| ROA % | -5.77 | |||||
| ROIC % | 14.42 | |||||
| ROC (Joel Greenblatt) % | -11.43 | |||||
| ROCE % | -2.97 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.63 | |||||
| PE Ratio without NRI | 23.53 | |||||
| Shiller PE Ratio | 193.5 | |||||
| PEG Ratio | 0.62 | |||||
| PS Ratio | 1.29 | |||||
| PB Ratio | 1.03 | |||||
| Price-to-Tangible-Book | 2.5 | |||||
| Price-to-Free-Cash-Flow | 4.59 | |||||
| Price-to-Operating-Cash-Flow | 4.35 | |||||
| EV-to-EBIT | -22.41 | |||||
| EV-to-EBITDA | 28.56 | |||||
| EV-to-Revenue | 1.37 | |||||
| EV-to-Forward-Revenue | 1.29 | |||||
| EV-to-FCF | 4.99 | |||||
| Price-to-Projected-FCF | 0.47 | |||||
| Price-to-Median-PS-Value | 0.25 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.02 | |||||
| Price-to-Graham-Number | 1.62 | |||||
| Earnings Yield (Greenblatt) % | -4.46 | |||||
| FCF Yield % | 25.3 | |||||
| Forward Rate of Return (Yacktman) % | 24.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pacira BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 637.216 | ||
| EPS (TTM) (€) | -1.788 | ||
| Beta | 0.2 | ||
| Volatility % | 54.2 | ||
| 14-Day RSI | 51.35 | ||
| 14-Day ATR (€) | 0.359277 | ||
| 20-Day SMA (€) | 15.88 | ||
| 12-1 Month Momentum % | -34.58 | ||
| 52-Week Range (€) | 10.7 - 32.2 | ||
| Shares Outstanding (Mil) | 46.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pacira BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pacira BioSciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pacira BioSciences Inc Frequently Asked Questions
What is Pacira BioSciences Inc(FRA:82P)'s stock price today?
The current price of FRA:82P is €15.80. The 52 week high of FRA:82P is €32.20 and 52 week low is €10.70.
When is next earnings date of Pacira BioSciences Inc(FRA:82P)?
The next earnings date of Pacira BioSciences Inc(FRA:82P) is 2025-02-28 Est..
Does Pacira BioSciences Inc(FRA:82P) pay dividends? If so, how much?
Pacira BioSciences Inc(FRA:82P) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers